Last reviewed · How we verify
Subcutaneous interferon-gamma
Subcutaneous interferon-gamma is an immunomodulatory agent being evaluated in multiple clinical trials for various conditions, including post-aggressive immunosuppression and ventilator-acquired pneumonia. Despite no FDA approval, it shows promise in treating Friedreich's ataxia and candidemia. The drug has a robust safety profile but requires monitoring for common side effects.
At a glance
| Generic name | Subcutaneous interferon-gamma |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subcutaneous interferon-gamma CI brief — competitive landscape report
- Subcutaneous interferon-gamma updates RSS · CI watch RSS
- NYU Langone Health portfolio CI